LifeMD (LFMD) investor relations material

Company overview and strategy

• Focuses on transforming healthcare delivery as a leading virtual primary care provider, with over 400 million interactions and 322,000 active patients, expanding into new care areas.

• Offers end-to-end virtual care, pharmacy, diagnostics, and branded GLP-1s for weight loss, with a growing women's health business and strong AI integration for provider support.

• Maintains a large, engaged medical group and a 50-state compounding pharmacy, with plans to expand or acquire more pharmacy capabilities.

• Leverages a significant untapped pool of former patients for re-engagement and growth opportunities.

• Board and leadership are highly engaged, with expertise in AI and healthcare innovation.

Technology and operational advantages

• Developed proprietary AI tools and a unified platform for revenue cycle and supply chain management, enabling rapid deployment and high-quality care.

• Integrated pharmacy operations deliver around 90% gross margins, with strong relationships with major pharma companies for GLP-1 drugs.

• Technology investments are prioritized, with plans to over-invest in tech leadership to maintain a competitive edge.

• Revenue cycle management is highly efficient, ranking in the top quartile for revenue capture.

Market expansion and growth areas

• Specialty care, including GLP-1 metabolic health, psychiatry, cardiology, and women's health, are key growth drivers.

• Women's health is identified as a major untapped market, with significant interest and potential for expansion.

• Psychiatry and mental health are early-stage but present large opportunities, leveraging the virtual care platform.

• Strategic collaborations with pharma companies position the business to capitalize on new drug pipelines and regulatory changes.